QYNAPSE Novel Imaging Software for Central Nervous System Diseases Receives FDA Clearance

The news regarding the QyScore® software was announced today by QYNAPSE.

QyScore® provides robust and precise analyses of brain MRI markers that intervene early in the process of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease or multiple sclerosis.

QYNAPSE advises that the software combines an advanced user interface with patient reports that are generated automatically in minutes. The results are presented in comparison to a healthy subject database, supporting neurologists and radiologists in their clinical decision-making. QyScore® is compatible with the clinical routine workflow to support differential diagnosis and measure of clinical progression and also used in clinical trials for monitoring of drug efficacy and safety.

According to Pr. Bruno Dubois, Professor of Neurology at Sorbonne University, and Director of the Memory and Alzheimer’s Disease Institute (IM2A) at Pitié Salpêtrière Hospital in Paris, “QyScore® makes a difference for the diagnosis of dementia at an early stage of the disease when it remains a challenge. The automatic quantification of markers such as brain atrophy, white matter hyperintensities and more, provides highly valuable help to support a timely diagnosis and efficient monitoring of disease progression.”

The software demonstrates its value by quantifying longitudinal changes of regions of interest in the brain, eliminating the inter- and intra-rater variability in images reading, and reducing the time and cost of image analysis notes QYNAPSE.

Commercialization of QyScore® started in Europe following the CE mark approval in September 2017.

“FDA clearance is a major milestone to expand the commercialization of the software within the U.S.,” said Olivier Courrèges, CEO of Qynapse. “Qynapse will accelerate collaboration with experts and healthcare providers in the U.S. to pursue its journey for better patient care in neurology.”

SourceQYNAPSE,
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy